Skip to content
AnalystLens

AMGN · AMGEN INC

50 filings

10-Q

AMGN 10-Q Quarterly Reports

AMGEN INC - 50 quarterly reports

Filing record · 2016–202610-K1210-Q328-K125

AMGN filed 12 annual reports (10-K), 32 quarterly reports (10-Q) and 125 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Jul ’18Jul ’18
  2. Deal closed8-K · Apr ’21Apr ’21
  3. Material agreement8-K · Jan ’23Jan ’23
  4. FY2024 annual report10-K · Feb ’25Feb ’25
  1. 2026-Q2

    AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2026

    Amgen Inc. reported strong financial results for the second quarter and first half of 2026, with total revenues reaching $10.05 billion and $18.67 billion, respectively. This represents significant year-over-year growth, driven primarily by robust product sales, which increased by 9% in the quarter and 7% year-to-date. Net income also saw substantial increases, up 66% for the quarter to $2.38 billion and 33% year-to-date to $4.19 billion, leading to a diluted EPS of $4.37 and $7.71 for the respective periods. The company's balance sheet remains strong, with cash and cash equivalents growing to $13.99 billion. However, investors should note the ongoing significant U.S. tax dispute with the IRS, which could materially impact future financial results if an unfavorable outcome occurs. The company also faces continued pressure from biosimilar competition for certain key products like Prolia and XGEVA, which are impacting their sales.

    Aug 5, 2026
  2. 2026-Q1

    AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2026

    Amgen Inc. reported solid financial results for the first quarter of 2026, demonstrating growth in total revenues and net income compared to the prior year. Total revenues increased by 6% to $8.62 billion, driven by a 4% rise in product sales and a significant 45% surge in other revenues. Net income grew by 5% to $1.82 billion, resulting in diluted earnings per share of $3.34, up from $3.20 in the first quarter of 2025. The company experienced strong volume growth in key products such as Repatha, EVENITY, and TEPEZZA, while also seeing substantial increases in newer products like UPLIZNA and IMDELLTRA/IMDYLLTRA. Despite the positive top-line and bottom-line growth, investors should note the significant decline in sales for Prolia and XGEVA, which are facing increased biosimilar competition following patent expiries. Operating expenses decreased by 15%, largely due to the absence of a significant intangible asset impairment charge recorded in the prior year, and lower amortization expenses, which helped bolster profitability. However, ongoing litigation, particularly the significant U.S. tax dispute, remains a critical area to monitor, with a decision expected in the second half of 2026. The company also highlighted progress in its pipeline, including positive Phase 3 results for TEPEZZA administered subcutaneously.

    May 1, 2026
  3. 2025-Q3

    AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2025

    Amgen Inc. reported strong financial performance for the third quarter and first nine months of 2025, with total revenues increasing by 12% and 11% year-over-year, respectively, driven primarily by robust volume growth across its key products. Net income saw significant increases, up 14% for the quarter and a substantial 84% for the nine-month period, leading to a corresponding surge in diluted Earnings Per Share (EPS). The company demonstrated effective cost management, with operating expenses growing at a slower pace than revenues. Strategic investments in late-stage clinical programs continue, supported by strong operational cash flow generation. The company's balance sheet remains solid, though cash and cash equivalents decreased slightly from year-end 2024, largely due to significant debt repayment and dividend payments. Amgen continues to manage its debt effectively, reducing its overall debt principal. The company also highlighted ongoing legal matters, particularly the significant U.S. Tax Court case, which, while expected to be resolved no earlier than the second half of 2026, continues to be a point of attention. Despite potential regulatory headwinds and ongoing litigation, Amgen's operational performance and strategic investments indicate a positive outlook for future growth.

    Nov 5, 2025
  4. 2025-Q2

    AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2025

    Amgen Inc. reported robust top-line growth for the second quarter and first half of 2025, with total revenues increasing by 9% and 10% respectively compared to the prior year periods. This growth was primarily driven by strong volume increases across key products, notably Repatha, EVENITY, BLINCYTO, and TEZSPIRE, which collectively offset modest net selling price declines. The company demonstrated significant profitability improvements, with net income soaring by 92% and 92% for the respective periods, and diluted EPS more than doubling year-over-year. This performance was supported by improved cost of sales as a percentage of revenue and well-managed selling, general, and administrative expenses, although R&D investments saw an increase. Despite the strong operational performance, investors should note the ongoing legal challenges, particularly the significant tax dispute with the IRS concerning past tax years, which continues through the judicial process. The company also faces ongoing patent litigations related to its key products like Repatha and Prolia/XGEVA, with several new biosimilar infringement lawsuits filed. While Amgen has a strong liquidity position with substantial cash and cash equivalents, its balance sheet reflects a notable decrease in cash from the prior year-end, largely due to significant debt repayments and dividend distributions. The company reiterated its commitment to capital allocation through debt reduction, dividends, and stock repurchases.

    Aug 6, 2025
  5. 2025-Q1

    AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2025

    Amgen Inc. reported a significant turnaround in the first quarter of 2025, with net income swinging from a loss of $113 million in Q1 2024 to a profit of $1.73 billion in Q1 2025. This substantial improvement was driven by a robust increase in total revenues, which grew by 9% year-over-year to $8.15 billion, primarily fueled by an 11% rise in product sales to $7.87 billion. The company's operating income also saw a healthy increase of 19% to $1.18 billion, reflecting effective cost management despite a notable $800 million impairment charge related to Otezla. The balance sheet shows a decrease in cash and cash equivalents to $8.81 billion from $11.97 billion, alongside a reduction in total debt. The company continues to prioritize shareholder returns, declaring a quarterly dividend of $2.38 per share, underscoring its commitment to financial health and shareholder value. Investors should note the ongoing legal proceedings, particularly the significant U.S. tax litigation, which remains a key area of focus, although a decision is not expected until the second half of 2026.

    May 2, 2025
  6. 2024-Q3

    AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2024

    Amgen Inc. reported a significant increase in total revenues for the third quarter of 2024, reaching $8.5 billion, up 23% year-over-year. This growth was primarily driven by a substantial 24% increase in total product sales, largely attributable to the successful integration of products acquired from Horizon Therapeutics. Key products like Repatha, EVENITY, BLINCYTO, and TEZSPIRE showed strong volume growth. Despite the revenue surge, net income saw a notable 64% increase to $2.83 billion, with diluted EPS rising to $5.22, reflecting improved operational efficiency and strategic asset contributions. However, operating expenses also grew significantly, up 32% in the quarter, largely due to higher amortization related to acquisition-related assets and increased R&D and SG&A spending. The company also reported a decrease in cash and cash equivalents to $9.0 billion from $10.9 billion at the end of the prior year, primarily due to debt repayments and dividend payments, though the company maintains ample liquidity. Investors should note the ongoing substantial legal and tax contingencies, particularly the IRS tax dispute, which continue to pose potential risks despite Amgen's belief in its strong legal standing.

    Oct 31, 2024
  7. 2024-Q2

    AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2024

    Amgen Inc. reported a notable increase in total revenues for the second quarter of 2024, reaching $8.4 billion, a 20% rise compared to the same period in the prior year. This growth was primarily driven by a significant 20% increase in product sales, largely attributable to the successful integration of Horizon Therapeutics and strong volume growth across key products. Despite the top-line expansion, operating income and net income experienced a decline due to a substantial increase in operating expenses, primarily driven by higher amortization related to the Horizon acquisition and increased R&D and SG&A expenses. Diluted EPS saw a corresponding decrease. The company's balance sheet shows a decrease in cash and cash equivalents to $9.3 billion from $10.9 billion at the end of 2023, alongside a reduction in total assets and stockholders' equity. Long-term debt also decreased. Amgen continued its commitment to capital allocation through dividend payments, though no shares were repurchased during the first half of 2024. The company remains focused on investing in innovation and managing its debt.

    Aug 7, 2024
  8. 2024-Q1

    AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2024

    Amgen Inc. reported a net loss of $113 million, or $(0.21) per share, for the first quarter of 2024, a significant shift from the $2.84 billion net income reported in the same period last year. This change was largely attributed to substantial non-cash charges, including unrealized losses on strategic equity investments and increased amortization and acquisition-related expenses stemming from the recent Horizon Therapeutics acquisition. Despite the net loss, total revenues grew by 22% year-over-year to $7.45 billion, driven by a 22% increase in product sales to $7.12 billion. The growth in product sales was primarily fueled by volume increases, with significant contributions from newly acquired Horizon products like TEPEZZA and KRYSTEXXA. Operationally, the company saw robust growth in key products such as Repatha (33% increase) and TEZSPIRE (80% increase), alongside contributions from the newly acquired Horizon portfolio. However, operating expenses surged by 54%, largely due to the impact of the Horizon acquisition, including higher amortization and acquisition-related costs, alongside increased R&D and SG&A expenses. The company also continues to navigate complex legal and tax matters, including an ongoing IRS tax dispute with potentially significant financial implications. Amgen's balance sheet remains solid, with substantial cash and cash equivalents, though debt levels remain elevated following the acquisition.

    May 3, 2024
  9. 2023-Q3

    AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2023

    Amgen Inc. reported total revenues of $6.9 billion for the third quarter of 2023, a 4% increase compared to the same period last year, driven by a 5% rise in product sales to $6.5 billion. For the nine-month period, total revenues grew by 3% to $19.99 billion. Net income for the third quarter was $1.73 billion, a decrease of 19% year-over-year, resulting in diluted EPS of $3.22. However, for the nine-month period, net income surged by 21% to $5.95 billion, with diluted EPS of $11.06, demonstrating strong performance over the year-to-date. A significant event during the quarter was the completion of the acquisition of Horizon Therapeutics plc on October 6, 2023, for approximately $27.8 billion. This strategic move is expected to bolster Amgen's inflammation portfolio with key treatments for rare inflammatory diseases. The company also made progress in its pipeline, announcing positive Phase 2 data for tarlatamab in small cell lung cancer and positive Phase 3 data for LUMAKRAS/LUMYKRAS in colorectal cancer.

    Oct 31, 2023
  10. 2023-Q2

    AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2023

    Amgen Inc. reported solid financial results for the second quarter and first half of 2023, demonstrating revenue growth driven by key products like Prolia and Repatha. Total revenues for the quarter rose 6% to $6.99 billion, with product sales increasing by 6% to $6.68 billion. For the first six months, total revenues grew 2% to $13.09 billion, and product sales were up 4% to $12.53 billion. Net income for the quarter was $1.38 billion, a 5% increase year-over-year, translating to diluted EPS of $2.57, up 5%. The first half of the year saw a substantial 51% increase in net income to $4.22 billion, with diluted EPS soaring 53% to $7.86. This strong performance was bolstered by a significant increase in cash from operations and strategic debt issuances related to the proposed acquisition of Horizon Therapeutics, alongside a notable increase in long-term debt. The company continues to navigate potential regulatory challenges, particularly the FTC's lawsuit seeking to block the Horizon acquisition, with a preliminary injunction hearing scheduled. Amgen also remains engaged in ongoing patent litigation and tax disputes, though the company expresses confidence in its legal positions and financial resilience.

    Aug 4, 2023
  11. 2023-Q1

    AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2023

    Amgen Inc. reported total revenues of $6.105 billion for the first quarter of 2023, a slight decrease from $6.238 billion in the same period of 2022. Despite the revenue dip, net income saw a significant increase, soaring to $2.841 billion ($5.28 diluted EPS) from $1.476 billion ($2.68 diluted EPS) in the prior year. This substantial earnings growth was largely driven by a substantial "Other income (expense), net" of $2.064 billion, primarily attributed to a significant unrealized gain from revaluing their investment in BeiGene. The company's strategic debt issuances totaling $24.0 billion in March 2023 were to finance the proposed acquisition of Horizon Therapeutics, which remains subject to regulatory review. Product sales showed modest growth of 2% to $5.846 billion, bolstered by strong performances from Prolia, Repatha, Nplate, and EVENITY. However, Enbrel and Otezla experienced declines. Operating expenses increased by 12% due to higher costs of sales, R&D investments, and expenses related to a restructuring plan. The company ended the quarter with a robust cash position of $31.6 billion, with a significant portion earmarked for the Horizon acquisition.

    Apr 28, 2023
  12. 2022-Q3

    AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2022

    Amgen Inc. reported solid financial results for the third quarter and first nine months of 2022, demonstrating resilience despite a challenging macroeconomic environment. Total revenues for the nine months increased by 2% year-over-year to $19.48 billion, driven by product sales growth and increased other revenues. Net income also saw a significant increase of 24% for the same period, reaching $4.94 billion, with diluted Earnings Per Share (EPS) rising to $9.11. The company's operating income showed substantial growth, up 38% for the nine-month period, reflecting effective cost management and operational efficiency. The company continued its strategic capital allocation through robust share repurchases and dividend payments, underscoring its commitment to returning value to shareholders. Amgen also made significant progress on its pipeline, highlighted by positive trial results for LUMAKRAS/LUMYKRAS. The recent acquisition of ChemoCentryx, Inc. for approximately $3.7 billion is expected to further enhance its therapeutic offerings in autoimmune diseases, inflammatory disorders, and cancer, positioning the company for future growth.

    Nov 4, 2022
  13. 2022-Q2

    AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2022

    Amgen Inc. reported solid financial results for the second quarter and first half of 2022. Total revenues grew modestly, driven by a 3% increase in product sales for both the quarter and the six-month period. This growth was primarily fueled by strong performance in key products like Prolia, Otezla, XGEVA, Repatha, and KYPROLIS, which experienced double-digit percentage increases in sales. Operating income saw a substantial increase of 58% for the six months ended June 30, 2022, largely due to the absence of a significant acquired in-process research and development (IPR&D) charge recorded in the prior year from the Five Prime acquisition. Diluted Earnings Per Share (EPS) also showed significant improvement, rising 41% for the six months. The company's balance sheet remains robust, though cash and cash equivalents decreased compared to the prior year-end, partly due to significant share repurchases. Amgen continued its commitment to returning capital to shareholders, repurchasing approximately $6.4 billion in stock and paying dividends during the first six months of the year. The company also announced a proposed acquisition of ChemoCentryx for approximately $4.0 billion, indicating a continued strategy of growth through business development. Despite positive operational performance, investors should note the ongoing significant U.S. Tax Court litigation concerning tax years 2010-2015, which could result in substantial additional tax liabilities if the IRS's position prevails. While Amgen believes its tax accruals are appropriate, this remains a notable risk factor.

    Aug 5, 2022
  14. 2022-Q1

    AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2022

    Amgen Inc. reported total revenues of $6.238 billion for the first quarter of 2022, an increase of 6% from $5.901 billion in the prior year period. This growth was primarily driven by a 64% surge in "Other revenues," largely attributable to COVID-19 antibody material sales, and a 2% increase in product sales to $5.731 billion. Despite the top-line growth, net income decreased by 10% to $1.476 billion, or $2.68 per diluted share, compared to $1.646 billion, or $2.83 per diluted share, in Q1 2021. The decrease in net income was influenced by higher interest expenses and net losses on strategic equity investments. Key operational highlights include continued growth in key products like Prolia, XGEVA, Repatha, and Kyprolis, which saw double-digit percentage increases in sales. However, Enbrel and Neulasta experienced sales declines, with Neulasta significantly impacted by biosimilar competition. The company also repurchased a substantial amount of its common stock, totaling $6.4 billion in the first quarter, and declared a quarterly dividend of $1.94 per share. Significant legal matters, particularly a tax dispute with the IRS, continue to be a point of attention, with the company contesting substantial proposed tax liabilities. Investors should note the strong revenue growth driven by non-core product sales, alongside a decline in profitability. While key growth products demonstrate positive momentum, the impact of biosimilar competition on established products like Neulasta remains a significant factor. The company's aggressive capital return program, including substantial stock repurchases, and the ongoing significant tax litigation are critical factors for investors to monitor.

    Apr 28, 2022
  15. 2021-Q3

    AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2021

    Amgen Inc. reported total revenues of $6.71 billion for the third quarter of 2021, a 4% increase compared to the same period in the prior year. This growth was driven by a 19% increase in Rest of World (ROW) product sales and a 21% increase in other revenues, largely attributed to sales of COVID-19 antibody material. However, net income decreased by 7% year-over-year to $1.88 billion, and diluted earnings per share (EPS) declined by 3% to $3.31. The nine-month period ending September 30, 2021, showed a 2% increase in total revenues to $19.13 billion, but a significant 29% drop in net income to $3.99 billion and a 27% decrease in diluted EPS to $6.93. This decline in profitability was significantly impacted by higher operating expenses, including $1.5 billion in acquired in-process research and development related to the Five Prime acquisition and a $400 million upfront payment for a licensing agreement with Kyowa Kirin. The company also faces ongoing significant legal challenges related to U.S. tax matters, with a potential tax liability of approximately $3.6 billion, plus interest, which could materially impact future financial statements. Amgen continues to return capital to shareholders through dividends and stock repurchases, with approximately $2.9 billion remaining under its stock repurchase program as of September 30, 2021. Subsequent to the quarter, the company announced an additional $4.5 billion authorization for repurchases. The company also completed the acquisition of Teneobio, Inc. for an upfront payment of $900 million, plus potential future milestone payments, to expand its pipeline in antibody therapeutics.

    Nov 3, 2021
  16. 2021-Q2

    AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2021

    Amgen Inc. reported total revenues of $6.53 billion for the second quarter of 2021, a 5% increase compared to the same period in the prior year, primarily driven by other revenues and growth in certain key products. However, net income and diluted Earnings Per Share (EPS) saw a significant decline of 74% and 73% respectively, to $464 million and $0.81 per share. This decrease is largely attributable to a substantial increase in operating expenses, notably $1.5 billion in acquired in-process research and development (IPR&D) related to the Five Prime Therapeutics acquisition. Despite the year-over-year dip in profitability for the quarter, the company demonstrated strong performance in specific product areas such as Prolia®, Repatha®, and XGEVA®, which showed double-digit percentage increases in sales. The company also continues to return capital to shareholders through dividends and an active stock repurchase program. Looking ahead, Amgen faces ongoing challenges including biosimilar competition for key drugs like Enbrel® and Neulasta®, and significant ongoing U.S. tax litigation with the IRS that could materially impact future financial results.

    Aug 4, 2021
  17. 2021-Q1

    AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2021

    Amgen Inc. reported total revenues of $5.901 billion for the first quarter of 2021, a decrease of 4% compared to $6.161 billion in the prior year period. This decline was primarily driven by a 5% decrease in total product sales, largely due to lower net selling prices for certain products, particularly Enbrel and Neulasta, and the ongoing impact of the COVID-19 pandemic on patient access and diagnoses. Despite the revenue dip, operating expenses saw a slight decrease of 1%, and net income stood at $1.646 billion, resulting in diluted Earnings Per Share (EPS) of $2.83, down from $3.07 in the prior year. The company demonstrated its commitment to returning capital to shareholders by repurchasing $865 million of common stock and declaring a quarterly dividend of $1.76 per share. Cash flow from operations remained robust at $2.104 billion. Amgen also advanced its strategic growth initiatives, notably completing the acquisition of Five Prime Therapeutics for approximately $1.9 billion to bolster its oncology pipeline. The company continues to navigate the uncertainties of the COVID-19 pandemic, which has impacted patient interactions and product demand, but believes its financial position remains adequate to meet its obligations and pursue future opportunities.

    Apr 28, 2021
  18. 2020-Q3

    AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2020

    Amgen Inc. reported solid revenue growth for the third quarter of 2020, with total revenues increasing by 12% year-over-year to $6.42 billion, driven by strong performance across several key products including Otezla, Prolia, and Repatha. Net income saw a modest increase to $2.02 billion, resulting in diluted earnings per share of $3.43. The company's balance sheet remains robust, with total assets growing to $64.6 billion and substantial cash, cash equivalents, and marketable securities totaling $12.4 billion. Amgen also continued its capital return program, repurchasing $2.3 billion in stock and paying dividends, while managing a significant debt load of approximately $34.2 billion.

    Oct 29, 2020
  19. 2020-Q2

    AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2020

    Amgen Inc. reported total revenues of $6.2 billion for the second quarter of 2020, a 6% increase compared to the same period last year, driven primarily by a 9% increase in total product sales. The company's net income for the quarter was $1.8 billion, or $3.05 per diluted share, representing a decrease of 17% and 15% respectively, from the prior year. This decline in profitability was influenced by higher operating expenses, notably cost of sales which rose significantly due to the amortization of expenses related to the Otezla acquisition. Despite the decrease in net income, the company demonstrated robust operating cash flow and maintained a strong liquidity position with $11.4 billion in cash, cash equivalents, and marketable securities. The acquisition of Otezla in late 2019 continues to significantly impact the financial results, contributing to revenue growth but also increasing operating expenses. The company also experienced a decrease in sales for some of its established products like ENBREL and Neulasta due to market dynamics and biosimilar competition. However, newer products such as Repatha and Otezla, along with contributions from other products, have shown strong growth, offsetting some of these declines. Amgen continues to manage its capital effectively through dividends and share repurchases while also investing in its pipeline and strategic collaborations, notably with BeiGene for oncology products in China.

    Jul 29, 2020
  20. 2020-Q1

    AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2020

    Amgen Inc. (AMGN) reported its first quarter 2020 results, showcasing a significant increase in total revenues driven by the acquisition of Otezla and growth in key products. Total revenues rose 11% year-over-year to $6.16 billion, primarily due to a 12% increase in product sales to $5.89 billion. This growth was bolstered by strong performances from Prolia®, Repatha®, and the newly acquired Otezla®, which generated $479 million in its first full quarter. However, net income saw a slight decrease of 8% to $1.83 billion, and diluted Earnings Per Share (EPS) declined by 3% to $3.07, largely impacted by increased operating expenses, particularly related to the Otezla acquisition and amortization of intangible assets. The company also highlighted its proactive capital allocation strategy, including significant share repurchases and dividend payments, while managing its debt profile. Amgen’s cash position remains robust, supporting ongoing operations and strategic investments. The company acknowledged the emerging impact of the COVID-19 pandemic, noting potential demand shifts for certain products and temporary pauses in clinical trial enrollments, while emphasizing its commitment to employee safety and business continuity. Despite the challenges posed by the pandemic, Amgen remains focused on its pipeline and strategic initiatives.

    May 1, 2020
  21. 2019-Q3

    AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2019

    Amgen Inc. reported third-quarter 2019 results with total revenues of $5.74 billion, a decrease of 3% year-over-year, primarily due to lower other revenues. Net income rose 6% to $1.97 billion, and diluted Earnings Per Share (EPS) increased by 14% to $3.27. For the first nine months of 2019, total revenues decreased by 2% to $17.17 billion, while net income declined 5% to $6.14 billion, and diluted EPS increased by 4% to $10.01. The company announced a significant development with an agreement to acquire worldwide rights to Otezla® for $13.4 billion, expected to close by year-end 2019, which is intended to expand its inflammation portfolio. The report also highlighted ongoing legal proceedings related to patent disputes and biosimilar competition, which could materially impact financial results. Amgen continued its capital return program, repurchasing $6.6 billion of its stock in the first nine months and declaring quarterly dividends.

    Oct 30, 2019
  22. 2019-Q2

    AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2019

    Amgen Inc. reported revenues of $5.87 billion for the third quarter of 2019, a decrease of 3% year-over-year, reflecting ongoing pressures from biosimilar competition, particularly impacting Neulasta® and Sensipar®/Mimpara® sales. Despite the top-line decline, the company demonstrated effective cost management, with operating expenses remaining relatively flat for the quarter. Diluted Earnings Per Share (EPS) saw a slight increase to $3.57, up 3% year-over-year, signaling operational efficiency and a strong focus on profitability. The company continued its robust capital return program, repurchasing $5.4 billion in common stock during the first six months of 2019 and increasing its authorized repurchase amount, demonstrating confidence in its future cash flows and commitment to shareholder value. The balance sheet remains solid, with total assets of $59.37 billion. While cash and cash equivalents decreased to $5.53 billion from $6.95 billion at year-end 2018, the company maintains substantial liquidity through marketable securities. Amgen is actively managing its debt, reducing long-term debt to $27.8 billion. The company's legal and regulatory landscape remains active, with ongoing patent litigations and potential impacts from pricing and reimbursement policies, which investors should monitor closely.

    Jul 31, 2019
  23. 2019-Q1

    AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2019

    Amgen Inc. reported a slight decrease in total revenues for the first quarter of 2019 compared to the same period in 2018, driven by a modest decline in product sales that was offset by an increase in other revenues, primarily royalties. While total revenues remained largely flat, net income and diluted Earnings Per Share (EPS) experienced a more significant decline, indicating pressure on profitability. This was attributed to a notable increase in operating expenses, particularly in Cost of Sales and Research & Development, impacting the bottom line. The company continued its capital return program, with substantial share repurchases and dividend payments. However, these activities, alongside operating costs, contributed to a decrease in cash and cash equivalents and marketable securities. Amgen faces ongoing challenges from biosimilar competition for key products like Neulasta® and Sensipar®/Mimpara®, which are impacting sales. Despite these headwinds, the company highlighted growth in Prolia® and KYPROLIS®, and strategic advancements such as the FDA approval of EVENITY™.

    May 1, 2019
  24. 2018-Q3

    AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2018

    Amgen Inc. reported a slight increase in total revenues for the nine months ended September 30, 2018, reaching $17.5 billion, a 3% rise from the prior year. This growth was primarily driven by product sales, which increased by 2% to $16.5 billion, with notable growth in Prolia®, XGEVA®, and 'Other products', partially offset by declines in ENBREL®, Neulasta®, Aranesp®, Sensipar®/Mimpara®, and EPOGEN®. The company's net income saw a more significant increase of 4% to $6.5 billion for the nine-month period, leading to a substantial 14% rise in diluted Earnings Per Share (EPS) to $9.61, reflecting the benefits of U.S. corporate tax reform. However, the third quarter of 2018 showed a slight dip in net income and a modest increase in diluted EPS compared to the prior year's quarter, highlighting sequential pressures. Financially, Amgen significantly strengthened its cash position, ending the period with $11.96 billion in cash and cash equivalents, a substantial increase from $3.8 billion at the end of 2017, primarily due to strong operating cash flows and strategic management of marketable securities. The company also continued its aggressive capital return strategy, repurchasing approximately $15.7 billion of its stock in the first nine months of 2018. The company is navigating patent expiries and increasing biosimilar competition for some of its key legacy products, which is reflected in sales trends for drugs like ENBREL and Neulasta®.

    Oct 31, 2018
  25. 2018-Q2

    AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2018

    Amgen Inc. reported solid revenue growth in the second quarter of 2018, with total revenues increasing by 4% year-over-year to $6.06 billion. This growth was primarily driven by a 10% increase in Rest of World (ROW) product sales and a significant 61% surge in other revenues, largely due to a milestone payment from Novartis for their migraine treatment, AimovigTM. Net income saw a healthy increase of 7% to $2.30 billion, leading to diluted EPS of $3.48, up 20% compared to the prior year, demonstrating improved profitability and effective cost management. The company also executed a substantial stock repurchase program, highlighting its commitment to returning capital to shareholders and a strong cash flow position.

    Jul 27, 2018
  26. 2018-Q1

    AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2018

    Amgen Inc.'s first quarter 2018 report shows robust financial performance with a notable increase in net income and diluted earnings per share compared to the prior year. Total revenues grew to $5.55 billion, driven by a 3% increase in product sales, primarily from higher unit demand, although some key products like Neulasta® and Enbrel® saw slight declines. The company also benefited from a significantly lower effective tax rate, a direct result of the U.S. Tax Cuts and Jobs Act of 2017. Operating expenses decreased, contributing to a 5% rise in operating income. Operationally, Amgen completed the acquisition of the remaining 50% of Kirin-Amgen, Inc., consolidating its operations and eliminating future royalty obligations. The company also continued its aggressive capital return program, repurchasing a substantial amount of its common stock and paying dividends. Management expressed confidence in future cash flows, supported by a strong financial position and ongoing investment in the business.

    Apr 25, 2018
  27. 2017-Q3

    AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2017

    Amgen Inc. reported relatively flat total revenues for the third quarter of 2017 compared to the prior year, with a slight decrease in product sales offset by an increase in other revenues. Net income also remained stable, but diluted Earnings Per Share (EPS) saw a modest increase due to a reduction in outstanding shares. The company's balance sheet reflects a solid cash position and significant investments in marketable securities. Operating expenses showed a slight increase due to specific charges, but underlying efficiency improvements were noted. Amgen continued its capital return strategy through dividends and share repurchases, demonstrating confidence in future cash flows. The company is navigating patent litigations and biosimilar competition, while also facing operational challenges and expenses related to Hurricane Maria in Puerto Rico.

    Oct 26, 2017
  28. 2017-Q2

    AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2017

    Amgen Inc. reported solid financial results for the second quarter and first half of 2017, demonstrating revenue growth and significant improvements in profitability. Total revenues for the three months ended June 30, 2017, increased by 2% to $5.81 billion, while net income saw a substantial 15% increase to $2.15 billion, translating to a diluted EPS of $2.91, up 18% from the prior year. The company's performance was driven by strong sales from key products such as Prolia®, Sensipar®/Mimpara®, Repatha®, and KYPROLIS®, which helped offset declines in established products like Enbrel® and Neulasta®. Operating expenses were well-managed, decreasing by 6% for the quarter due to efficiency improvements and the expiration of residual royalty payments. This operational efficiency contributed to a 13% increase in operating income. Amgen continues to focus on returning capital to shareholders, with significant stock repurchases and dividend payments, while maintaining a robust cash position.

    Jul 26, 2017
  29. 2017-Q1

    AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2017

    Amgen Inc. reported its first-quarter 2017 financial results, showcasing solid performance with a net income of $2.07 billion, or $2.79 per diluted share, a notable increase from the prior year. Total revenues slightly declined by 1% to $5.46 billion, primarily due to a decrease in other revenues, while product sales remained largely stable. The company demonstrated effective cost management, with operating expenses down 8% year-over-year, leading to an 8% increase in operating income. Key product sales showed mixed performance, with strong growth in Prolia® (21%) and Sensipar®/Mimpara® (15%), while Enbrel® experienced a significant decline (15%) due to competition. The company continued to return capital to shareholders through dividends and stock repurchases. Amgen also highlighted significant progress in its pipeline and regulatory submissions, including an expanded indication for XGEVA® and positive cardiovascular outcomes data for Repatha®.

    Apr 27, 2017
  30. 2016-Q3

    AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2016

    Amgen Inc. reported solid financial performance for the third quarter and the first nine months of 2016, demonstrating revenue growth and improved profitability. Total revenues for the nine months increased by 6% to $17.0 billion, driven by a 4% rise in product sales and a significant 56% increase in other revenues, largely attributed to milestone payments and royalty income. Net income for the nine-month period rose by 13% to $5.8 billion, translating to a 14% increase in diluted Earnings Per Share (EPS) to $7.63. This growth was supported by effective cost management, with operating expenses remaining flat year-over-year due to ongoing transformation and process improvement initiatives, which are expected to yield further cost savings. The company also continued to return capital to shareholders through substantial stock repurchases and increased dividend payments, signaling confidence in its financial health and future prospects.

    Oct 28, 2016
  31. 2016-Q2

    AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2016

    Amgen's Q2 2016 10-Q shows continued top-line growth and strong profitability. Total revenues rose 6% to $5.69 billion for the quarter (8% to $11.2 billion for the first half), driven by ENBREL, Prolia, KYPROLIS and XGEVA, plus higher other revenues from licensing upfronts and Ibrance royalties. Operating income grew 15% to $2.38 billion, and diluted EPS increased 15% to $2.47, helped by transformation-related savings and a lower effective tax rate of 15.2%. Cost of sales and R&D fell as a share of revenue, while SG&A rose 11% on new product launch investments. The balance sheet and capital allocation remain central to the story. Cash and marketable securities reached $35.0 billion, but total debt rose to $33.2 billion after new euro, Swiss franc and a $5.1 billion U.S. dollar exchange of senior notes that extended maturities and lowered coupons. Management returned $1.5 billion in dividends and $1.2 billion in buybacks in the first half, with $3.6 billion left on the repurchase authorization. Amgen also declared a $1.00 quarterly dividend for Q3. Key risks are concentrated in U.S. competition from biosimilars and new entrants. ENBREL growth was offset by unit declines, while EPOGEN sales fell 33% and NEUPOGEN fell 23%. Neulasta faces pegfilgrastim biosimilar entry after its final U.S. patent expired in October 2015. Ongoing patent litigation against Sandoz, Apotex and Hospira, and Puerto Rico's fiscal crisis affecting the Juncos manufacturing site, are additional watch items. Restructuring charges remain on track at $800-900 million total.

    Jul 29, 2016
  32. 2016-Q1

    AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2016

    Amgen Inc. reported strong financial results for the first quarter of 2016, with total revenues increasing by 10% to $5.53 billion and net income growing by 17% to $1.90 billion. Diluted earnings per share (EPS) also saw a significant increase of 18% to $2.50. This growth was driven by a 7% increase in product sales, reaching $5.24 billion, with key products like Enbrel, Prolia, and Aranesp showing robust performance. The company also benefited from an 81% surge in other revenues, largely due to an upfront partner payment and increased royalty income. Despite a 4% increase in operating expenses, the company's operating income grew by 19%, demonstrating effective cost management and revenue expansion. Amgen continued its commitment to returning capital to shareholders, declaring a quarterly dividend and actively engaging in stock repurchases.

    May 2, 2016
  33. 2015-Q3

    AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2015

    Amgen's Q3 2015 10-Q shows a strong quarter driven by top-line growth and operating leverage. Total revenues rose 14% year over year to $5.72 billion for the three months ended September 30, 2015, and net income grew 50% to $1.86 billion, with diluted EPS of $2.44 versus $1.61. For the nine months, revenues were $16.1 billion (+9%) and diluted EPS was $6.70 (+33%). Growth was led by ENBREL (+30% in the quarter), Prolia, Sensipar, XGEVA and Kyprolis, while the restructuring plan and lower operating expenses (down 5% in the quarter) helped margins. Operating income rose 60% in the quarter to $2.34 billion. The balance sheet remains substantial but leveraged. Cash, equivalents and marketable securities total $31.1 billion against $31.8 billion of total debt. Management returned capital through $1.8 billion of dividends and $1.7 billion of share repurchases in the nine months, and in October raised the buyback authorization to $5.0 billion. Roughly $30.0 billion of cash sits in foreign jurisdictions and would incur U.S. tax if repatriated. Key risks are forward-looking. Neulasta faces biosimilar competition after its final U.S. patent expired in October 2015, EPOGEN faces competition following its May 2015 patent expiry, and NEUPOGEN already faces a biosimilar from Sandoz. The filing also flags Puerto Rico's fiscal crisis as a risk to the Juncos manufacturing site, and it discloses the subsequent $300 million cash acquisition of Dezima Pharma (with up to $1.25 billion in milestones) and the termination of brodalumab co-development with AstraZeneca.

    Nov 2, 2015
  34. 2015-Q2-A

    AMGEN INC Quarterly Report (Amendment) for Q2 Ended Jun 30, 2015

    This filing represents an amendment to Amgen Inc.'s (AMGN) Quarterly Report on Form 10-Q for the period ending June 30, 2015. The primary purpose of this amendment is to provide a corrected Exhibit 10.18, an agreement between Amgen Inc. and Jonathan Graham dated May 11, 2015. No other financial information or disclosures within the original Form 10-Q are altered by this amendment. Investors should note that this filing does not introduce new financial performance data or operational updates for the second quarter of 2015. The original Form 10-Q, filed on August 5, 2015, would contain the substantive financial and operational details. This amendment focuses solely on the correction of a specific exhibit, ensuring the completeness and accuracy of the SEC filing record.

    Aug 6, 2015
  35. 2015-Q2

    AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2015

    Amgen's Q2 2015 10-Q shows a quarter of solid top-line and profit growth. Total revenues rose 4% to $5.37 billion and product sales rose 6% to $5.23 billion, led by U.S. sales (+9%). Operating income climbed 9% to $2.08 billion, and diluted EPS increased 7% to $2.15. For the six months, revenue grew 7%, operating income rose 25%, and diluted EPS reached $4.26 versus $3.41. Much of the operating leverage came from restructuring-driven savings, with R&D down 5% in the quarter and 9% year to date, though the company is investing in new launches and business development. Growth drivers were ENBREL (+8%), Prolia (+29%), XGEVA (+11%), Sensipar (+15%) and Kyprolis (U.S. +49%). Offsetting pressures include biosimilar competition to NEUPOGEN from Sandoz's Zarxio, short-acting competition, EPOGEN unit declines, and Other Revenues falling 37% after the Nexavar co-promotion ended. The Nexavar arrangement with Bayer moved to a royalty on U.S. sales, and the brodalumab program with AstraZeneca is being terminated after suicidal ideation events. Neulasta's U.S. U.S. patent expires in October 2015, and Apotex has filed for a pegfilgrastim biosimilar. Balance sheet and capital returns are strong. Cash and marketable securities total $30.0 billion against $32.0 billion of debt, after a $3.5 billion May bond issuance used partly to repay $2.15 billion of the Term Loan. Operating cash flow was $4.1 billion for the first half, and Amgen repurchased $966 million of stock and paid $1.2 billion in dividends. Key near-term catalysts include the Repatha PDUFA date of August 27, 2015, the talimogene laherparepvec PDUFA date of October 27, 2015, and the Sandoz injunction, which runs through September 2, 2015.

    Aug 5, 2015
  36. 2015-Q1

    AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2015

    Amgen's first-quarter 2015 results showed strong top-line and profit growth. Total revenues rose 11% to $5.03 billion, driven by a 12% increase in product sales to $4.87 billion, with U.S. product sales up 15%. Operating income climbed 48% to $2.02 billion as operating expenses fell 5% to $3.01 billion, reflecting savings from the ongoing restructuring plan. Net income increased 51% to $1.62 billion, and diluted EPS rose to $2.11 from $1.40. Growth was broad-based across the portfolio. ENBREL (+13%), Prolia (+39%), XGEVA (+22%), EPOGEN (+16%), Sensipar (+24%) and newer products such as Kyprolis (+56% in the U.S.) contributed meaningfully, while Neulasta/NEUPOGEN was flat. Management flagged emerging headwinds, including the approaching October 2015 expiration of Neulasta's U.S. patent, Zarxio's FDA approval as a filgrastim biosimilar, the May 2015 expiry of EPOGEN's remaining U.S. patent, and a trebananib ovarian cancer study being stopped for futility. Restructuring charges of $92 million were incurred in the quarter, with $650 million recognized to date against a $935 million to $1.035 billion total estimate. Balance sheet and capital returns remain central to the investment case. Cash and marketable securities totaled $27.1 billion against $30.3 billion of gross debt. The company paid $599 million in dividends ($0.79 per share) and repurchased $464 million of stock, leaving $3.4 billion authorized. Operating cash flow was $1.33 billion, and the effective tax rate rose to 13.5% from 10.9%. Roughly $24.6 billion of cash sits offshore and would face U.S. tax if repatriated.

    Apr 27, 2015
  37. 2014-Q3

    AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2014

    Amgen's Q3 2014 10-Q shows a quarter with solid top-line growth but sharply lower profitability. Total revenues rose 6% to $5.03 billion, driven by product sales growth of 4% (Prolia up 43%, XGEVA up 22%, Kyprolis newly contributing $94 million) and other revenues up 81%. However, operating income fell 13% to $1.47 billion and net income declined 9% to $1.24 billion, with diluted EPS down 10% to $1.61. Margin pressure stems from acquisition-related amortization from the Onyx deal (cost of sales up 36%), a $376 million restructuring charge, and a $145 million accelerated Branded Prescription Drug fee accrual recorded in SG&A. Nine-month results were more resilient, with revenues up 8% and diluted EPS down 5% to $5.02. The filing highlights a significant strategic reset. Amgen announced a restructuring plan that now targets a reduction of 3,500 to 4,000 staff by the end of 2015, with total pre-tax charges estimated at $935 million to $1.035 billion, roughly 55% cash-based. Balance sheet activity was substantial: Amgen issued $4.5 billion of notes in May and repurchased the $3.1 billion ATL Holdings preferred shares, with total debt rising to $33.0 billion. Liquidity remains strong at $28.1 billion in cash and marketable securities, though about $25.4 billion is held offshore. Management also raised the buyback authorization to $4.0 billion in October and reinstated repurchases, a notable signal of confidence in cash generation. Key risks include U.S. competition for NEUPOGEN after patent expiry (with Neulasta's remaining U.S. patent expiring October 2015 and EPOGEN's in May 2015), the execution risk of the restructuring, and several pending litigations, including new patent suits against Sanofi and Regeneron over PCSK9 antibodies and a biosimilar suit against Sandoz. Overall, the quarter reflects near-term earnings pressure from integration and restructuring costs against a stronger long-term growth profile and cash position.

    Oct 29, 2014
  38. 2014-Q2

    AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2014

    Amgen's second-quarter 2014 results (three months ended June 30, 2014) show growth on the top line and operating line, driven by the Onyx acquisition and strong sales of ENBREL, Prolia, XGEVA and Kyprolis. Total revenues rose 11% to $5.18 billion, product sales rose 8% to $4.95 billion, and operating income rose 23% to $1.90 billion. Diluted EPS was $2.01, up 22% from $1.65, though net income for the first half declined 3% year-over-year because of favorable tax items recorded in Q1 2013. Gross margin compression is notable: cost of sales rose to 21.8% of product sales from 17.1%, reflecting roughly $203 million of quarterly non-cash amortization of Onyx intangibles. Operating cash flow for the six months rose to $3.37 billion from $2.65 billion. The balance sheet strengthened in some respects and changed shape in others. Cash, equivalents and marketable securities totaled $26.2 billion, against $33.3 billion of total debt. Amgen issued $4.5 billion of notes in May 2014 and used the proceeds to repurchase Class A preferred shares of ATL Holdings for $3.1 billion, which eliminated the restricted investments and the related Master Repurchase Agreement. Management also declared a $0.61 quarterly dividend and indicated no significant buybacks are planned for the rest of 2014 or 2015. Roughly $23 billion of cash sits in foreign tax jurisdictions, which would face U.S. tax if repatriated. The most important subsequent event is a July 2014 restructuring plan to cut 2,400 to 2,900 jobs by the end of 2015, close facilities in Washington and Colorado, and reduce headquarters buildings in Thousand Oaks. It carries pre-tax charges of $775 million to $950 million, about 40% of which will be cash. Key regulatory and pipeline events include the FDA approval of Vectibix in first-line mCRC, a Breakthrough Therapy designation for blinatumomab, a positive ASPIRE Phase 3 interim analysis for Kyprolis, and a U.S. BLA for talimogene laherparepvec. Investors should also note U.S. filgrastim patent expiration and emerging biosimilar competition, and a pending securities class action.

    Aug 5, 2014
  39. 2014-Q1

    AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2014

    Amgen's Q1 2014 10-Q shows total revenues up 7% to $4.52 billion, driven by product sales growth of 5% to $4.36 billion, with U.S. sales up 4% and rest-of-world up 9%. The top line benefited from the October 2013 Onyx acquisition (Kyprolis) and from XGEVA, Prolia and Neulasta growth. Profitability was weaker: operating income fell 5% to $1.36 billion, and net income dropped 25% to $1.07 billion, or $1.40 diluted EPS (down 26%). The earnings decline reflects a sharp rise in cost of sales (up 47%, to 25.0% of product sales), driven largely by $219 million of non-cash amortization from acquired Onyx intangibles and a $99 million charge from terminating the Roche supply contract. The prior-year quarter also included favorable one-time tax items, which makes the year-over-year comparison look worse than underlying operations. Underlying demand was mixed. Enbrel sales fell 5% on lower U.S. unit demand, and Neupogen declined 3% after U.S. patent expiry in December 2013. Growth came from XGEVA (+25%), Prolia (+38%), Neulasta (+3%) and EPOGEN (+6%), while Aranesp fell 2%. The company ended the quarter with $19.8 billion in cash and marketable securities against $32.0 billion of total debt, and generated $1.14 billion of operating cash flow. It paid $460 million in dividends ($0.61 per share), funded roughly $445 million of net securities and restricted-investment purchases, and made no buybacks, with $1.6 billion remaining under its authorization. Management also disclosed that the phase 3 talimogene laherparepvec melanoma trial missed its overall survival secondary endpoint, and a $275 million payment to GSK to terminate the denosumab collaboration in most territories was agreed after quarter-end. For investors, the key questions are whether Onyx and the Roche product-rights deal lift revenue enough to outweigh the amortization and cost drag, how fast U.S. filgrastim erosion and the expected 2014 MIRCERA competition hit EPOGEN and Aranesp, and whether the pipeline (evolocumab, blinatumomab, brodalumab) can offset pressure on the mature franchises.

    Apr 30, 2014
  40. 2013-Q3

    AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2013

    Amgen's Q3 2013 10-Q shows solid top-line and profit growth, led by Neulasta/NEUPOGEN, ENBREL, and the XGEVA/Prolia franchise. Total revenues rose 10% to $4.75 billion in the third quarter and 6% to $13.67 billion for the nine months. Product sales grew 11% in the quarter, helped by a $155 million U.S. government stockpile order for NEUPOGEN. Operating income rose 19% to $1.69 billion, and diluted EPS increased 27% to $1.79, aided by a lower share count from 2012 and early 2013 buybacks. Nine-month results were also lifted by a $164 million favorable Medicaid rebate adjustment and a low effective tax rate of 4.5%, which includes one-time benefits, so the quarterly tax rate of 9.0% is the cleaner run-rate indicator. The filing's most important item for investors is the balance sheet and capital structure shift tied to the Onyx Pharmaceuticals acquisition, which closed October 1, 2013 for about $9.7 billion net cash. Amgen financed the deal with $1.6 billion of cash on hand, a $3.1 billion Master Repurchase Agreement (accounted for as long-term debt, due 2018), and a $5.0 billion Term Loan. Total long-term debt rose to $27.2 billion from $24.0 billion at year-end 2012, while cash and marketable securities fell to $22.6 billion. Management also said it does not expect significant buybacks through 2015, a notable change in capital return policy, though the quarterly dividend of $0.47 continues. Looking ahead, the key risk is the U.S. patent expiry for NEUPOGEN in December 2013, with competition expected from the fourth quarter of 2013. Management also flagged the Puerto Rico excise tax increase, potential EPOGEN pressure from a Medicare dialysis payment change, and a Q4 2013 timeline for several late-stage catalysts, including evolocumab data in early 2014. Trebananib enrollment changes and a Sandoz patent dispute add pipeline and legal uncertainty.

    Oct 29, 2013
  41. 2013-Q2

    AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2013

    Amgen's second-quarter 2013 results show modest top-line growth driven by product sales, offset by weaker other revenues and rising operating costs. Total revenues rose 5% to $4.68 billion for the quarter, with product sales up 9% to $4.60 billion, led by ENBREL, Neulasta/NEUPOGEN, XGEVA and Prolia. Other revenues fell 70% to $84 million, reflecting a prior-year Takeda motesanib collaboration gain. Operating income declined 2% to $1.55 billion as R&D rose 17% (largely AMG 145 late-stage programs) and other operating expenses included a $110 million increase in contingent consideration tied to talimogene laherparepvec. Net income was roughly flat at $1.26 billion, while diluted EPS rose 2% to $1.65, helped by a 3% reduction in diluted shares from buybacks. For the six months, net income rose 10% to $2.69 billion and diluted EPS rose 14% to $3.52, but this was flattered by a very low 2.0% effective tax rate, which benefited from a one-time IRS settlement and reinstated R&D tax credit. Excluding the Puerto Rico excise tax, the six-month tax rate would have been 7.5%, so the tax benefit is largely non-recurring and investors should not extrapolate it. Operating income for the half was down 2%, underscoring that underlying profit growth is pressured by R&D spending and the ENBREL profit share payable to Pfizer. Balance sheet and cash flow are solid but weaker in cash generation. Cash, equivalents and marketable securities were $22.0 billion against $23.9 billion of debt, after the $2.5 billion repayment of the 0.375% 2013 convertible notes. Operating cash flow fell 21% to $2.65 billion for the half. Looking ahead, NEUPOGEN faces U.S. generic competition beginning Q4 2013, the Aranesp demand trend is softening, and the Sandoz etanercept patent suit adds legal risk, while late-stage catalysts include trebananib, AMG 145 and talimogene data in 2014.

    Aug 6, 2013
  42. 2013-Q1

    AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2013

    Amgen's first-quarter 2013 results showed solid top-line growth and a sharply lower effective tax rate that drove a much larger jump in earnings. Total revenues rose 5% to $4.24 billion, led by a 6% increase in product sales to $4.15 billion. ENBREL (+11%), XGEVA (+46%) and Prolia (+61%) drove the growth, while Aranesp (-10%) and EPOGEN (-2%) declined and Neulasta/NEUPOGEN was flat. Operating income fell 2% to $1.44 billion because operating expenses rose 9%, mainly from R&D (+19%) and SG&A (+7%). Net income rose 21% to $1.43 billion and diluted EPS rose 27% to $1.88, but the improvement was largely due to a tax benefit: the effective tax rate was (6.8)%, versus 13.3% a year earlier, reflecting the IRS settlement and reinstatement of the federal R&D credit. Excluding the Puerto Rico excise tax effect, the underlying rate was (0.8)% versus 18.5%, so investors should view the tax-driven earnings lift as largely non-recurring. Balance sheet and capital return were the other major themes. Amgen repaid the $2.5 billion 0.375% convertible notes in February 2013, leaving total debt at $23.9 billion, down from $26.5 billion at year-end. Cash, cash equivalents and marketable securities declined to $21.3 billion from $24.1 billion, and about $17.9 billion of that balance sits offshore. Amgen returned capital through $832 million of buybacks (9.1 million shares at an average of $85.03) and $353 million of dividends, and it declared a $0.47 quarterly dividend. Operating cash flow was $1.05 billion, up from $972 million. Looking ahead, the key pipeline catalyst was positive phase 3 top-line data for talimogene laherparepvec in melanoma (16% vs. 2% durable response rate), with overall survival data expected in late 2013. The main medium-term risk is U.S. competition for NEUPOGEN beginning in Q4 2013, which could eventually pressure Neulasta. Other watch items include the ENBREL co-promotion expiring October 31, 2013, after which royalties are expected to be significantly lower than current profit-share costs, and ongoing pressure from Southern European government payment delays.

    May 3, 2013
  43. 2012-Q3

    AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2012

    Amgen's Q3 2012 10-Q shows strong top-line and earnings momentum. Total revenues rose 10% to $4.32 billion for the quarter and 11% to $12.84 billion for the nine months, while diluted EPS was $1.41 versus $0.50 a year earlier. The comparison is flattered by a $780 million legal settlement reserve booked in Q3 2011, so the year-over-year EPS jump is far larger than underlying growth. Underlying growth was more moderate: U.S. product sales grew 10% in the quarter, ENBREL rose 17%, and the Takeda motesanib modification added $232 million of other revenue for the nine months. Operating income for the nine months rose 43% to $4.49 billion, though the Puerto Rico excise tax continues to weigh on cost of sales. The balance sheet and capital allocation changed meaningfully during the period. Total debt climbed to $26.5 billion from $21.4 billion after roughly $5 billion of new issuance, partly to fund $10 billion of buybacks and a $2.5 billion convertible note maturing in Q1 2013. Cash and marketable securities of $25.4 billion still exceed debt, but about $18.8 billion of that cash sits offshore. Amgen also completed three acquisitions (Micromet, Mustafa Nevzat and KAI) for roughly $2.2 billion in total consideration, and it repurchased 48.1 million shares for $3.4 billion in the nine months. Key risks flagged in the filing are the expected U.S. NEUPOGEN patent expiry in late 2013, biosimilar pressure in Europe, continued ESA declines in the U.S., and slow collections from southern European government payers. Amgen also disclosed a pending settlement of federal investigations and qui tam actions, with $806 million accrued as of September 30, 2012. The Sensipar E.V.O.L.V.E. cardiovascular trial missed its primary endpoint on an intent-to-treat basis, and the company reported strong phase 2 LDL-lowering data for AMG 145.

    Nov 6, 2012
  44. 2012-Q2

    AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2012

    Amgen Inc. reported solid financial results for the second quarter and first half of 2012, demonstrating revenue growth driven by key products like Enbrel, Neulasta/Neupogen, and a notable increase in "Other products." Total revenues for the quarter rose 13% year-over-year to $4.48 billion, with net income up 8% to $1.27 billion. Diluted EPS saw a significant 29% increase to $1.61, largely due to a reduced share count from aggressive share repurchases. The company also announced the strategic acquisitions of Micromet, Inc. and Mustafa Nevzat Pharmaceuticals, bolstering its oncology and Turkish market presence, respectively. Despite facing patent expirations on some principal products, Amgen's financial strength is evident in its robust operating cash flow and significant cash reserves, positioning it for continued investment in innovation and return of capital to shareholders.

    Aug 8, 2012
  45. 2012-Q1

    AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2012

    Amgen Inc. reported solid financial results for the first quarter of 2012, demonstrating revenue growth and improved profitability. Total revenues increased by 9% year-over-year to $4.05 billion, driven by an 8% rise in product sales, primarily from key products like Neulasta®/NEUPOGEN® and ENBREL®. Operating income saw a significant 14% increase, leading to a 5% rise in net income to $1.18 billion. Diluted Earnings Per Share (EPS) also showed strong growth, increasing by 23% to $1.48, largely due to the company's effective stock repurchase program which reduced the share count. Strategically, Amgen made a significant move by acquiring Micromet, Inc. in March 2012 to bolster its oncology pipeline, and also entered into a key collaboration with AstraZeneca for the development of monoclonal antibodies in inflammation. While the company faces ongoing challenges such as the decline in sales for its erythropoiesis-stimulating agents (ESAs) like Aranesp® and EPOGEN®, and the increasing cost of sales due to the Puerto Rico excise tax, the overall performance indicates a resilient business with a focused approach on strategic growth and innovation.

    May 8, 2012
  46. 2011-Q3-A

    AMGEN INC Quarterly Report (Amendment) for Q3 Ended Sep 30, 2011

    Amgen Inc. filed an amendment to its Form 10-Q for the quarterly period ended September 30, 2011. This amendment primarily addresses the re-filing of Exhibit 10.47, an amendment to a Master Services Agreement with International Business Machines Corporation, after discussions with the SEC regarding confidential treatment. The company has provided a revised version of the exhibit with less redaction and included its schedules and exhibits. For investors, this filing does not introduce new financial results or operational updates for the period. Its significance lies in the procedural correction and the updated disclosure of material contractual information related to Amgen's IT services. Investors should refer to the original 10-Q filing from November 4, 2011, for the company's financial performance and operational highlights for the September 30, 2011 quarter.

    Mar 15, 2012
  47. 2011-Q3

    AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2011

    Amgen Inc.'s third quarter 2011 results showed a significant decrease in net income, primarily driven by a $780 million legal settlement charge related to sales and marketing practices. Despite this, total revenues grew 3% year-over-year to $3.94 billion, with product sales increasing 3% to $3.88 billion, largely supported by strong performance in Neulasta®/NEUPOGEN® and ENBREL, which offset declines in EPOGEN® and Aranesp®. The company demonstrated solid cash flow generation, with $3.54 billion in cash from operations for the nine-month period. Amgen continued its commitment to returning capital to shareholders, with $3.15 billion in share repurchases and the initiation of a quarterly dividend. The company also made strategic acquisitions, including BioVex Group, Inc., to bolster its pipeline, particularly in oncology. Looking ahead, Amgen faces ongoing challenges from the decline in its erythropoiesis-stimulating agents (ESAs) and potential impacts from healthcare reform and evolving global economic conditions. However, the company's strategic investments in R&D and recent product launches like XGEVA® and Prolia® indicate a focus on future growth drivers.

    Nov 4, 2011
  48. 2011-Q2

    AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2011

    Amgen's second-quarter 2011 10-Q shows steady top-line growth but weaker profitability. Total revenues rose 4% to $3.96 billion for the quarter, driven by U.S. product sales (up 6% to $2.98 billion) and Neulasta/NEUPOGEN, ENBREL, XGEVA and Prolia. Operating income fell 12% to $1.33 billion and net income declined 3% to $1.17 billion. Diluted EPS was flat at $1.25 because the 12.9 million shares repurchased in the quarter reduced the share count. The main margin drags were a new Puerto Rico excise tax on manufacturing (which hits cost of sales), the U.S. Healthcare Reform Federal Excise Fee, higher ENBREL profit-share expense and rising R&D spending on late-stage programs. The effective tax rate fell to 12.6% for the quarter, helped by Puerto Rico excise tax credits. The most important development for investors is the ESA franchise. The FDA approved label changes in June 2011 that call for lower hemoglobin targets for dialysis patients, and CMS has proposed removing a dialysis quality measure. Management expects EPOGEN dose utilization to fall 20% to 25% in 2011 versus 2010. Management says this will be partly offset by patient growth and higher net prices. ESA-related sales are already declining, with EPOGEN U.S. sales down 16% in the six-month period. Other pipeline and regulatory events were mixed. The FDA issued Complete Response Letters for Vectibix first- and second-line mCRC, and Amgen terminated the phase 3 OncoVEX GM-CSF head and neck trial. On the positive side, XGEVA was approved in the EU, and sNDA was submitted for bone metastasis prevention in prostate cancer. On capital allocation, Amgen repaid $2.5 billion of 2011 convertible notes and issued $3.0 billion of new senior notes. It acquired BioVex (OncoVEX) and several other businesses for about $453 million plus $701 million of cash for acquisitions in the six months. It repurchased $745 million of stock, leaving $6.4 billion authorized. Cash and marketable securities were $19.2 billion against $13.9 billion of debt. The board also declared Amgen's first quarterly dividend of $0.28 per share, payable September 8, 2011.

    Aug 8, 2011
  49. 2011-Q1

    AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2011

    Amgen's first-quarter 2011 10-Q shows total revenues of $3.706 billion, up about 3% from $3.592 billion a year earlier, driven by U.S. product sales growth in Neulasta/NEUPOGEN, ENBREL, XGEVA and Prolia, partly offset by lower EPOGEN and Aranesp sales. Operating income fell 13% to $1.293 billion and net income declined 4% to $1.125 billion, mainly due to higher SG&A (including a $39 million U.S. Healthcare Reform Excise Fee and $39 million of Prolia/XGEVA promotional costs), higher R&D, and higher cost of sales. Diluted EPS rose to $1.20 from $1.18 only because of a lower share count from prior buybacks. The effective tax rate fell to 13.9% from 17.8%, aided by Puerto Rico excise-tax credits that the company says favorably affected Q1 EPS by roughly $0.06. The balance sheet and capital allocation picture changed meaningfully. Amgen repaid the $2.5 billion 2011 Convertible Notes in February, leaving total borrowings at $10.9 billion versus $13.4 billion at year-end 2010. Cash, cash equivalents and marketable securities declined to $15.4 billion from $17.4 billion, partly due to the repayment and the $403 million cash cost of the BioVex acquisition. Stockholders' equity rose to $25.0 billion. Management also announced a new quarterly dividend policy (initial payment expected with Q2 2011 results) and a fresh $5.0 billion buyback authorization, bringing total available repurchase capacity to $7.2 billion. Investors should weigh the growth in the core franchises against pressure from ESA (EPOGEN/Aranesp) demand erosion tied to the Medicare dialysis bundling rule and a pending CMS National Coverage Determination decision due by June 16, 2011. Other watch items include a negative EMA opinion on Vectibix in Europe, the failed MONET1 phase 3 trial for motesanib, and an ongoing IRS examination. Approximately $13.6 billion of cash sits offshore, so repatriation would carry U.S. tax costs.

    May 10, 2011
  50. 2010-Q3

    AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2010

    Amgen Inc. reported steady revenue growth for the nine months ended September 30, 2010, with total revenues increasing by 3% to $11.212 billion compared to the same period in 2009. While total revenues remained flat year-over-year for the third quarter, the company demonstrated strong operational performance. Net income for the nine-month period saw a slight decrease of 2% to $3.605 billion, primarily impacted by a higher effective tax rate. Diluted Earnings Per Share (EPS) for the nine months increased by 4% to $3.71, benefiting from a reduced share count due to active stock repurchases. The company's balance sheet shows a healthy financial position with total assets of $43.534 billion and total stockholders' equity of $24.071 billion as of September 30, 2010. Cash and cash equivalents, along with marketable securities, stood at $17.049 billion, providing ample liquidity. Amgen continued to return value to shareholders through its stock repurchase program, with $2.7 billion spent on repurchases during the first nine months of 2010.

    Nov 8, 2010